1-Phenyl-4-{7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}piperazine

Catalog No. :
ACTNNM758
CAS No. :
338403-70-6
Molecular Formula :
C21H20N6
Molecular Weight :
356.43

IUPAC Name:7-phenyl-2-(4-phenylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidine

1-Phenyl-4-{7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Phenyl-4-{7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}piperazine
IUPAC Name7-phenyl-2-(4-phenylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyrimidine
MDL No.MFCD00172135
Molecular FormulaC21H20N6
Molecular Weight356.43
SMILESN1(C2=CC=CC=C2)CCN(C3=NN4C(C5=CC=CC=C5)=CC=NC4=N3)CC1
InChI KeyRLPVOAFKNMFXGU-UHFFFAOYSA-N
Synonym7-PHENYL-2-(4-PHENYLPIPERAZINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE;1-phenyl-4-{7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}piperazine;[1,2,4]Triazolo[1,5-a]pyrimidine, 7-phenyl-2-(4-phenyl-1-piperazinyl)-
CAS No.338403-70-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACTNNM758 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTNNM758 route product structure diagram
    ACTNNM758338403-70-6
Inquiry

2. ACTNNM758 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTNNM758 route product structure diagram
    ACTNNM758338403-70-6
Inquiry

Comments (0)